Home : DrugWatch : Symlin : Newsfeeds

Symlin - Newsfeeds

Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global ...: SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat ...
Amylin Pharmaceuticals Announces Online Summit: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage ...
Amylin Pharmaceuticals to Present at the Goldman Sachs 31st Annual Global Healthcare Conference: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage ...
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's ...: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLINÂ® (pramlintide acetate) injection and BYETTAÂ® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's ...: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
Amylin Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals ...: The BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection are the two medicines marketed by the company to treat diabetes. Its products are sold through a network of wholesale distributors. Amylin Pharmaceuticals products are sold ...
Amylin Pharmaceuticals Inc. Reports Operating Results (10-Q): Amylin has developed and gained approval for two first-in-class medicines for diabetes SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies ...
Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse ...: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
Takeda Agrees to Buy Rights to Amylin’s Obesity Drugs (Update3): ... experimental therapy that combines the diabetes drug Symlin with a form of leptin, a hormone implicated in weight ... pancreas cells to make insulin when blood sugar is high. Once-Weekly Version Amylin and Lilly are trying to gain U.
Anti-fat Hormones May Fight Obesity By Controling Appetite: Amylin Pharma is testing a combination of their proprietary drug pramlintide acetate (an amylinomimetic, on the market as Symlin) and metreleptin. The hormone amylin is cosecreted by pancreatic beta-cells along with insulin. Alone, amylin has three ...

Amylin Pharmaceuticals Q1 Loss Narrows: Net product sales of $179.3 million for the quarter include $157.7 million for Byetta or exenatide injection and $21.6 million for Symlin or pramlintide acetate injection. Revenues under collaborative agreements for the first-quarter of fiscal ...
Interim Study Results Presented At ADA 2009: Exenatide Not Associated ...: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review: The company is principally engaged in the development and marketing of innovative medicines for the treatment of diabetes, obesity and other diseases. The BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection are the two medicines ...
Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
ObamaCare: $4 trillion in costs: • Insulin pumps are being used for infusing pramlintide (brand name Symlin, or synthetic amylin) with insulin for improved postprandial glycemic control compared to insulin alone. • An insulin pump that can be surgically implanted inside the body will ...
Amylin Pharmaceuticals Reports Second Quarter Financial Results: This includes net product sales of $376.8 million, including $332.8 million for BYETTA and $44.0 million for SYMLIN. This compares to net product sales of $379.1 million, consisting of $336.0 million for BYETTA and $43.1 million for SYMLIN for the ...
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging ...: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
America's Coolest Beach Homes: The Phase II, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of pramlintide, the active ingredient in Symlin, a drug used to treat diabetes, and metreleptin, a synthetic analog of the human hormone leptin ...
Amylin Pharmaceuticals to Webcast Second Quarter Results: Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in ...
BUYINS.NET: MICC, IBKC, AMLN, WCN, PTP, VOCS Expected To Be Higher ...: It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including ...

Looking for a Symlin lawyer in Washington, DC? Get in touch with one of our Symlin lawyers in Washington, DC now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 Next

Need A Symlin Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Symlin Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Symlin Information

Click to View Our Legal Resources

Looking for a Symlin lawyer in Washington, DC? Get in touch with one of our Symlin lawyers in Washington, DC now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120223-061730

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Symlin Click to select a Legal Issue

Close (x)

Find Legal Help for Your Symlin Case - Submit Your Information Below

Do you need legal assistance with your Symlin case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Symlin Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.